Outpatient CAR T-Cell Therapy Associated With Lower Short-Term Costs in DLBCL
Key Clinical Summary:
- A real-world study of 269 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) found that inpatient administration of chimeric antigen receptor (CAR) T-cell therapy was associated with 17.6% higher total costs at 30 days and 18.9% higher costs at 60 days compared with outpatient administration.
- Mean all-cause costs following CAR T-cell therapy were $468,223 at 30 days and $474,290 at 60 days, with inpatient services accounting for most medical expenditures.
- Although outpatient administration was associated with greater ambulatory care utilization, overall costs were lower, suggesting potential opportunities to improve resource allocation and expand access to CAR T-cell therapy.
Outpatient administration of CAR T-cell therapy was associated with lower short-term health care costs than inpatient administration among patients with relapsed or refractory DLBCL, according to a real-world US claims analysis.
The study, Inpatient Versus Outpatient Administration of CAR T-cell Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma: Real-World 30- and 60-Day Costs and Resource Utilization, examined differences in health care resource utilization and expenditures across treatment settings. The findings highlight potential opportunities for managed care organizations and health systems to optimize CAR T-cell therapy delivery while addressing the substantial financial burden associated with these treatments.
Real-World Analysis Compares CAR T-Cell Treatment Settings
Researchers conducted a retrospective claims analysis using the Optum Research Database and third-party administrator data collected between July 2017 and April 2024.
The study included 269 adults with DLBCL who received CAR T-cell therapy with lisocabtagene maraleucel, axicabtagene ciloleucel, or tisagenlecleucel.
Eligible patients were required to have at least 2 claims documenting a DLBCL diagnosis and continuous health insurance enrollment for at least 90 days before their first CAR T-cell infusion.
Investigators evaluated all-cause health care resource utilization and costs at 30 and 60 days following treatment, comparing patients who received CAR T-cell therapy in inpatient versus outpatient settings.
Multivariable generalized linear models adjusted for age, sex, and comorbidity burden to estimate differences in treatment-related expenditures.
Inpatient Administration Associated With Higher Costs
Across the study population, mean all-cause costs were $468,223 at 30 days among 267 patients who survived at least 30 days and $474,290 at 60 days among 253 patients who survived at least 60 days.
Inpatient stays accounted for approximately 82% to 83% of medical costs, demonstrating the substantial contribution of hospital-based care to overall CAR T-cell expenditures.
After adjustment for demographic characteristics and comorbidity burden, inpatient administration was associated with 17.6% higher total costs at 30 days compared with outpatient administration (P = .044).
At 60 days, inpatient administration was associated with 18.9% higher costs (P = .037).
Older age was also independently associated with lower expenditures. Patients aged 65 years or older had approximately 25% lower costs, although the study did not establish the reasons for this association.
These findings suggest that treatment setting may be an important factor influencing early CAR T-cell therapy costs.
Outpatient Treatment Increases Ambulatory Utilization
Although outpatient administration was associated with lower overall costs, patients treated in this setting required more outpatient visits.
At 30 days, patients receiving outpatient CAR T-cell therapy had a mean of 23.6 outpatient visits compared with 9.4 among patients treated in the inpatient setting.
At 60 days, outpatient visit counts increased to 31.9 and 20.2, respectively.
The distribution of expenditures also differed substantially between treatment settings.
Among patients receiving outpatient CAR T-cell therapy, outpatient services accounted for 89.1% of costs, while inpatient services represented approximately 8%.
In contrast, 98.6% of follow-up costs among patients initially treated in the inpatient setting were attributed to inpatient services.
The findings indicate that outpatient administration shifts a greater proportion of care toward ambulatory services while potentially reducing the overall financial burden associated with treatment.
However, outpatient treatment still requires substantial monitoring and clinical resources, emphasizing the importance of appropriate patient selection and coordinated care delivery.
Implications for Managed Care
The findings provide real-world evidence relevant to managed care organizations evaluating CAR T-cell therapy delivery models and associated expenditures.
CAR T-cell therapies require specialized infrastructure, multidisciplinary coordination, and monitoring for potentially serious adverse events. Consequently, treatment setting can influence both resource utilization and overall costs.
The lower expenditures associated with outpatient administration suggest potential opportunities for health systems to expand ambulatory CAR T-cell services when clinically appropriate.
For payers, these findings may inform discussions about site-of-care policies, reimbursement arrangements, and strategies to improve access to specialized oncology treatments.
Expanding outpatient administration could also potentially reduce geographic barriers by supporting treatment delivery beyond traditional inpatient models, although the study did not directly evaluate geographic access or patient travel burdens.
Several limitations should be considered. The retrospective observational design cannot establish that outpatient administration directly caused lower costs. Although the analysis adjusted for age, sex, and comorbidity burden, differences in disease severity, treatment selection, and clinical characteristics may have influenced treatment setting and expenditures.
Additionally, the analysis focused on patients who survived to the respective 30- and 60-day assessment points and did not evaluate long-term outcomes or comparative clinical effectiveness.
Further research examining safety, patient selection, treatment outcomes, and longer-term expenditures is needed to determine which patients may benefit most from outpatient CAR T-cell therapy.
Conclusion
This real-world analysis found that inpatient CAR T-cell therapy administration was associated with significantly higher costs at 30 and 60 days compared with outpatient administration among patients with relapsed or refractory DLBCL.
Although outpatient treatment required more ambulatory visits, overall expenditures were lower, highlighting the potential economic benefits of alternative CAR T-cell delivery models.
The findings support further evaluation of outpatient CAR T-cell therapy as a strategy to optimize health care resource utilization and potentially expand access to advanced oncology treatments.
Reference
Ghione P, Meier G, Palivela M, et al. Inpatient versus outpatient administration of CAR T-cell therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): real-world 30- and 60-day costs and resource utilization. Transplant Cell Ther. 2026;32(2). doi:10.1016/j.jtct.2025.12.254


